Merck's Keytruda Qlex, a subcutaneous formulation of its flagship cancer immunotherapy, has received FDA approval, offering a one-minute injection alternative to the traditional 30-minute intravenous infusion. This advancement enables faster administration while maintaining comparable efficacy to the original formulation. The FDA clearance marks a significant convenience milestone for clinicians and patients, potentially increasing treatment accessibility and adherence for various solid cancers. This clearance builds on Keytruda’s established commercial success.